IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. Appln. N Confirmation U.S. Filing D	ate : 06/27/2003) Art Unit:) Examiner:	1614 Edward J. Webman			
	Title of Invention: Medicament Compositions Containing Anticholinergically-effective Compounds and Betamimetics Attny. Docket No.: 1/1088-3-C2					
Mail Stop Amendment Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450						
March 15, 20	07					
TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT						
Sir.						
In accordance with the duty of disclosure under 37 C.F.R. \S 1.56, Applicant hereby notifies the U.S. Patient and Trademark Office of the documents listed herein and on the attached from PTO-SB08 and which the Examiner may deem relevant to patentability of the claim of the above-identified application.						
☐ 1.97(b). This Statement is being filed: j) within three (3) months of the filing date of a national application other than a continued prosecution application under 33 C.F. §15.3 (d); ii) within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; iii) before the mailing of a first Office action after the filing of a request fixenization under 37 C.F.R. §1.114.						
∑ 1.97(c). This Statement is being filed after the time period specified in 37 CFR, §1.97(b), but before the mailing date of: i) a final action under 37 CFR, §1.13, in notice of allowance under 37 CFR, §1.311, or iii) notice of allowance under 37 CFR, §1.311, or iii) no action that otherwise closes prosecution in the application. This Statement is being accompanied by:						
	A statement as specified in 37 C	C.F.R. §1.97(c) [se	e below]; or			
\boxtimes	The fee set forth in 37 C.F.R. §	1.17(p).				

	The Director is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
§1.97(c)	.97(d). This Statement is being filed after the period specified in 37 C.F.R. but on or before payment of the issue fee. This Statement is accompanied by a t as specified in 37 C.F.R. §1.97(c) [see below] and the fee set forth in 37 C.F.R.
☐ 1.	.97(e).
C	Each item of information contained in the instant information disclosure latement was first cited in any communication from a foreign patent office in a ounterpart foreign application not more than three (3) months prior to the filing of he instant information disclosure statement; or
fè m ir C	No item of information contained in the instant information disclosure tatement was cited in a communication from a foreign patent office in a counterpart roreign application, and, to the knowledge of the person signing this certification after tasking reasonable inquiry, so item of information contained in the instant solution that the properties of the properties of the properties of the properties of the properties of the properties of the properties of the properties of the properties of the properties of the properties of properties of properties propertie
	The fee set forth in 37 C.F.R. §1.17(p).
	☐ The Director is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
disclosur counterpoints in section	7.04(d). Each item of information contained in the accompanying information re statement was cited in a communication from a foreign patent office in a rart application, which communication was not received by any individual designated in 1.5e(e) more than thirty (30) days prior to the filing of the accompanying ion disclosure statement.

The Director is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Respectfully submitted,

/wendy petka/

Wendy Petka Attorney for Applicants Reg. No. 53,549

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road, P.O. Box 368 Ridgefield, CT 06877 Tel: (203) 791-6614 Fax: (203) 798-4408

Approved for use through 07/31/2006, OMB 0851-0031 U.S. Palent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

U.S. Petert and Trademark Office, U.S. DEPARTMENT OF COMMERC U.S. Petert and Trademark Office, U.S. DEPARTMENT OF COMMERC Substitute for form 14404-07TO.

Complete if Known

INFORMATION DISCLOSURE

(Use as many sheets as necessary)

 Application Number
 10/608,753

 Filing Date
 06/27/2003

 First Named Inventor
 Karl-Heinz BOZUNG

 Art Unit
 16/4

Examiner Name E. WEBMAN
Altomey Docket Number 1/1088-3-C2

U. S. PATENT DOCUMENTS						
xaminer nibals*	No.1	Document Number Number-Kind Code ^{2 (Finces)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Otted Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		^{US-} 6,908,928	06/21/2005	Banholzer, Rolf, et al		
		US-6,777,423	08/17/2004	Banholzer, Rolf, et al		
		US- 4,814,161	03/21/1989	Jinks, Philip, A., et al		
		^{US-} 5,795,564	08/18/1998	Aberg, Gunnar, et al		
	П	^{US-} 6,537,524	03/25/2003	Hassan, Ian, F., et al		
		US- 2002/0052312	05/02/2002	Reiss, Thomas, et al		
		^{US-} 6,303,103	10/16/2001	Akehurst, Rachel A., et a		
		US- 2003/0066524	04/10/2003	Hochrainer, Dieter, et al		
		^{US-} 2005/0159441	07/21/2005	Hochrainer, Dieter, et al		
		^{US-} 6,481,435	11/19/2002	Hochrainer, Dieter, et al		
		US- 2004/0087793	05/06/2004	Banholzer, Rolf, et al		
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ³ (Finower)	Publication Date MMI-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶	l
		WO 97/47286	12/18/1997	Minnesota Mining & M			1
]
							1
						Г	1
	T					_	1

Signature Daile Considered

TOURDER! In this if retrieves consistent, whether or not distin in a continuous and MEPI 600. One for Impai station for an incrinance and the continuous and the properties impaid and the continuous and t

This collection of exhaustion is required by 27 CFR 127 and 128. The enhaustion is required to before or exhaustion between 150 in 150 kin cardy by 60 collection of exhaustion in regiments and position confidence in the 2 hours to regime the 250 collection of exhaustion in the 2 hours to regime the 250 collection of exhaustion of the 250 collection of exhaustion o

Approved for use through 06/30/2006, OMB 0651-0031

U.S. Petent and Trademark Office; U.S. DEPARTMENT OF COMMERC Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number				
Substitute for form 1449B/PTO		Complete if Known		
	Application Number	10/608,753		
INFORMATION DISCLOSURE	Filing Date	06/27/2003		
STATEMENT BY APPLICANT	First Named Inventor	Karl-Heinz BOZUNG		
	Art Unit	1614		
(Use as many sheets as necessary)	Examiner Name	E MEDMAN		

Attorney Docket Number 1/1088-3-C2 Sheet d NON PATENT LITERATURE DOCUMENTS Examiner include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book Cite magazine, journal, senal, symposium, catalog, etc.), date, page(s), volume-assue number(s), publisher, city Initials* No. and/or country where published SCHMELZER, CHRISTEL; et al; U.S. Application No. 10/054,567, Pharmaceutical Compositionis based on Tiotropium Salts and Salts of Salmeterol filed 11/13/2001, Attorney Docket NO, 1/1171 SCHMELZER, CHRISTEL; Office Action dated March 30, 2006 for U.S. Application 10/054,567 Pharmaceutical Compositionis based on Tiotropium Salts and Salts of Salmeterol filed 11/13/2001 Attorney Docket NO. 1/1171

Evaminer	Date	
Examiner Signature	Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not clabion is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of his form with next communication to applicate.

*Applicant's unique clation designation number (optional). 2 Applicant or make replace has quite properties. The properties of the properti

This collection of information is required by 2 CGH 1.57 and 1.58. The information is required to bottom or stress a leveral by the public which is the first only the SCH 1.50 or processing a supervised by 2 CGH 1.57 and 1.58. The collections is explained to take 2 hower to complete.

The collection is explained to take 2 hower to complete the complete to the collection of the collection is explained to take 2 hower to complete the complete to the collection of the collection